Lyon: Raised the target price of China Biopharmaceuticals (01177.HK) to 7 Hong Kong dollars while maintaining an "outperform" rating.

According to the Wise Finance APP, Lyon released a research report stating that the revenue forecasts for China Biopharmaceutical (01177.HK) in 2026 and 2027 have been respectively increased by 10.2% and 3.9%, while the net profit forecasts have been raised by 48.1% and 15.6%. The target price-to-earnings ratio has been raised from 23 times to 25 times to reflect the positive impact of volume-based procurement policies on the generic drug business and significant improvement in the market sentiment for innovative drugs. The target price has been raised from 4.8 Hong Kong dollars to 7 Hong Kong dollars, maintaining an "outperform market" rating.